Rock Roc Biotechnology

ROC ROCK Biotechnology, led by European-returning Chinese scientists, is a biomedicine strategic high-tech enterprise founded in collaboration with PhDs from multiple research institutions and pharmaceutical companies such as Sweden's Karolinska Institutet, the European Molecular Biology Laboratory, Germany’s Max Delbrück Center for Molecular Medicine, and Hong Kong Baptist University. Relying on over a decade of cutting-edge interdisciplinary research achievements by its scientific team, the company is committed to a closed-loop industrial chain model centered around macrophage research. It focuses on chimeric antigen receptor macrophage therapy, promoting the application of macrophages in clinical and anti-aging fields, and realizing the industrial transformation of its findings. The core team has established platforms for targeted macrophage therapy in solid tumors, a macrophage secretion platform, and a database for screening macrophage lineage differentiation. With a rich pipeline of research and development, the company holds core competitiveness in macrophage-targeted solid tumor therapies. ROC ROCK Biotechnology aims to successfully bring two innovative drugs to market within 5-6 years.